Page last updated: 2024-11-06

trospectomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

trospectomycin: active against Neisseria gonorrhoeae; RN refers to 2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9beta,9alpha,9aalpha,10abeta)-(9CI)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID55886
CHEMBL ID1614655
CHEBI ID135577
SCHEMBL ID149850
MeSH IDM0127415

Synonyms (37)

Synonym
trospectomycin sulfate
(2r,4ar,5ar,6s,7s,8r,9s,9ar,10as)-2-butyl-4a,7,9-trihydroxy-6,8-bis(methylamino)-3,5a,6,7,8,9,9a,10a-octahydro-2h-benzo[[?]]pyrano[[?]][1,4]dioxin-4-one
trospectomycin
4h-pyrano[2,3-b][1,4]benzodioxin-4-one, 2-butyldecahydro-4a,7,9-trihydroxy-6,8-bis(methylamino)-, (2r,4ar,5ar,6s,7s,8r,9s,9ar,10as)-
(2r,4ar,5ar,6s,7s,8r,9s,9ar,10as)-2-butyldecahydro-4a,7,9- trihydroxy-6,8-bis(methylamino)-4h-pyrano[2,3-b][1, 4]benzodioxin-4-one
trospectinomycin
spectinomycin deriv u6633f(b)
u6633(f)b
CHEBI:135577
u-63366
u-63,366
CHEMBL1614655
trospectomycinum [latin]
trospectomycine [french]
trospectomicina
5s94mc2frg ,
trospectomycin [inn:ban]
trospectomycine
4h-pyrano(2,3-b)(1,4)benzodioxin-4-one, 2-butyldecahydro-4a,7,9-trihydroxy-6,8-bis(methylamino)-, (2r,4ar,5ar,6s,7s,8r,9s,9ar,10as)-
4h-pyrano(2,3-b)(1,4)benzodioxin-4-one, 2-butyldecahydro-4a,7,9-trihydroxy-6,8-bis(methylamino)-, (2r-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))-
trospectomycinum
unii-5s94mc2frg
trospectomicina [spanish]
88669-04-9
4h-pyrano(2,3-b)(1,4)benzodioxin-4-one, 2-butyldecahydro-4a,7,9-trihydroxy-6,8-bis(methylamino)-, (2r-(2.alpha.,4a.beta.,5a.beta.,6.beta.,7.beta.,8.beta.,9.alpha.,9a.alpha.,10a.beta.))-
(2r,4ar,5ar,6s,7s,8r,9s,9ar,10as)-2-butyldecahydro-4a,7,9-trihydroxy-6,8-bis(methylamino)-4h-pyrano(2,3-b)(1,4)benzodioxin-4-one
trospectomycin [vandf]
trospectomycin [mi]
trospectomycin [inn]
SCHEMBL149850
DTXSID20869010
rubidiumnitrate
u63366f
gtpl10870
4h-pyrano(2,3-b)(1,4)benzodioxin-4-one, 2-butyldecahydro-4a,7,9-trihydroxy-6,8-bis(methylamino)-, (2r-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))-
Q27262806
(1r,3s,5r,8r,10r,11s,12s,13r,14s)-5-butyl-8,12,14-trihydroxy-11,13-bis(methylamino)-2,4,9-trioxatricyclo[8.4.0.03,8]tetradecan-7-one

Research Excerpts

Overview

Trospectomycin sulfate is a 6' propyl analogue of spectinomycin with potent activity against penicillin sensitive and resistant strains of N. gonorrhoeae. Trospectomycins sulfate has been shown to induce the formation of cytoplasmic lamellar bodies in rat and dog liver in subchronic experiments.

ExcerptReferenceRelevance
"Trospectomycin sulfate is a 6' propyl analogue of spectinomycin with potent activity against penicillin sensitive and resistant strains of N."( Efficacy of 250 mg trospectomycin sulfate i.m. vs. 250 mg ceftriaxone i.m. for treatment of uncomplicated gonorrhea.
Caine, VA; Colletta, L; Hook, EW; Jones, RB; Linnemeier, P; Neumann, T; Rompalo, AM,
)
1.18
"Trospectomycin sulphate is a new, more potent analog of spectinomycin, which is active in vitro against penicillin-sensitive and penicillin-resistant strains of Neisseria gonorrhoeae. "( Treatment of gonococcal infections with a single 250 mg intramuscular injection of trospectomycin sulphate vs ceftriaxone sodium.
Leonik, KJ; Martin, DH; Millikan, LE; Mroczkowski, TF, 1993
)
1.95
"Trospectomycin is an aminocyclitol analog of spectinomycin with significant in vitro activity against Chlamydia trachomatis. "( Single-dose trospectomycin for chlamydial urethritis in men.
Keefer, MC; Long, M; Menegus, MA; Nasello, MA; Reichman, RC; Reid, JA, 1991
)
2.1
"Trospectomycin sulfate is an experimental, aminocyclitol antibiotic. "( Distribution and disposition of trospectomycin sulfate in the in vivo rat, perfused rat liver, and cultured rat hepatocytes.
Constable, DA; Cox, JW; Dring, LG; Ginsberg, LC; Larson, PG; Ulrich, RG,
)
1.86
"Trospectomycin sulfate is a novel aminocyclitol antibiotic. "( Multiple-dose, double-blind, placebo controlled intravenous tolerance and pharmacokinetic study of trospectomycin sulfate (U-63, 366F) in healthy male volunteers.
Batts, DH; Bye, A; Francom, SF; Nichols, DJ; Novak, E; Peters, GR, 1990
)
1.94
"Trospectomycin sulfate is an experimental aminocyclitol antibiotic which has been shown previously to induce the formation of cytoplasmic lamellar bodies in rat and dog liver in subchronic experiments. "( Reversible, hepatic, lysosomal phospholipidosis in rat induced by subchronic daily administration of trospectomycin sulfate.
Cox, JW; Epps, DE; Ginsberg, LC; Larsen, ER; McKenna, R; Ulrich, RG; Wynalda, MA, 1989
)
1.94
"Trospectomycin (U-63366F) is a novel spectinomycin analog with broad-spectrum antibacterial activity. "( In vitro antibacterial activity of trospectomycin (U-63366F), a novel spectinomycin analog.
Vavra, JJ; Wentworth, BB; Yagi, BH; Zurenko, GE, 1988
)
1.99

Toxicity

ExcerptReferenceRelevance
" Adverse drug experiences reported by subjects included nausea, dizziness, light-headedness, diaphoresis, costal pain, and perioral numbness."( Human safety and pharmacokinetics of a single intramuscular dose of a novel spectinomycin analog, trospectomycin (U-63,366F).
Bye, A; Francom, SF; Novak, E; Patel, R; Paxton, LM; Zurenko, GE, 1990
)
0.5
" Investigational toxicology methods, using appropriate models and hypotheses, can often resolve problems, identify toxic chemical substituents and salvage therapeutic discovery programs."( Cultured hepatocytes as investigational models for hepatic toxicity: practical applications in drug discovery and development.
Bacon, JA; Cramer, CT; Peng, GW; Petrella, DK; Stryd, RP; Sun, EL; Ulrich, RG, 1995
)
0.29

Pharmacokinetics

Trospectomycin has an initial half-life of 1. After a 1,000-mg intravenous dose of trospectomyin, the mean serum half- life was 2.

ExcerptReferenceRelevance
" Pharmacokinetic calculations based on data obtained by high-performance liquid chromatography showed that after a 1,000-mg intramuscular dose of trospectomycin (3."( Human safety and pharmacokinetics of a single intramuscular dose of a novel spectinomycin analog, trospectomycin (U-63,366F).
Bye, A; Francom, SF; Novak, E; Patel, R; Paxton, LM; Zurenko, GE, 1990
)
0.7
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Dosage Studied

ExcerptRelevanceReference
" An intermediate category was proposed for MICs greater than 2-4 micrograms/m (28-32 mm) pending more clinical experience with higher and/or prolonged cefmetazole dosing regimens."( Cefmetazole and trospectomycin in vitro susceptibility testing interpretive criteria and quality control guidelines for Neisseria gonorrheae.
Erwin, ME; Gerlach, EH; Jones, RN; Koontz, FP; Murray, PR; Washington, JA,
)
0.48
" dosing was rapid."( Pharmacokinetics of trospectomycin sulphate in healthy subjects after single intravenous and intramuscular doses.
Bye, A; Nichols, DJ; Novak, E, 1991
)
0.6
" dosing was only approximately 75% but there were few other biologically significant differences between the routes of administration."( Pharmacokinetics and fate of 3H-trospectomycin sulphate, a novel aminocyclitol antibiotic, in male and female rats.
Burrows, M; Bye, A; Constable, DA; Dring, LG; Jeffrey, P; Nichols, DJ, 1991
)
0.56
" Rats were treated for 30 or 90 days with 0, 50, or 250 mg/kg/day of trospectomycin sulfate prior to being killed, and another group was dosed for 90 days and then allowed to recover for 79 days prior to sacrifice."( Reversible, hepatic, lysosomal phospholipidosis in rat induced by subchronic daily administration of trospectomycin sulfate.
Cox, JW; Epps, DE; Ginsberg, LC; Larsen, ER; McKenna, R; Ulrich, RG; Wynalda, MA, 1989
)
0.73
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dioxanes
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID643383Induction of phospholipidosis in bovine corneal fibroblasts assessed as lamellar inclusion bodies after 72 hrs by light microscopy2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (47)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (31.91)18.7374
1990's28 (59.57)18.2507
2000's1 (2.13)29.6817
2010's3 (6.38)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.94 (24.57)
Research Supply Index4.19 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (10.17%)5.53%
Reviews1 (1.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other52 (88.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]